Potential Clinical Impact of Compounded Versus Noncompounded Intrathecal Baclofen

Archives of Physical Medicine and Rehabilitation

Volumn 90, Issue 11, 2009, Pages 1815-1820

  Moberg Wolff, Elizabeth ^a  

^a MEDICAL COLLEGE OF WISCONSIN   (United States)

Author keywords

Pharmacy; Rehabilitation

Indexed keywords

BACLOFEN;

ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG MANUFACTURE; DRUG PACKAGING; DRUG STORAGE; FOOD AND DRUG ADMINISTRATION; PHARMACY; RANDOM SAMPLE;

BACLOFEN; DRUG COMPOUNDING; DRUG LABELING; DRUG STABILITY; DRUG STORAGE; HUMANS; INJECTIONS, SPINAL; MUSCLE RELAXANTS, CENTRAL; UNITED STATES;

EID: 70449420084     PISSN: 00039993     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.apmr.2009.05.018     Document Type: Article

References (31)

1. Albright A.L., Gilmartin R., Swift D., Krach L.E., Ivanhoe C.B., and McLaughlin J.F. Long-term intrathecal baclofen therapy for severe spasticity of cerebral origin. J Neurosurg 98 (2003) 291-295
2. Coffey J.R., Cahill D., Steers W., et al. Intrathecal baclofen for intractable spasticity of spinal origin: results of a long-term multicenter study. J Neurosurg 78 (1993) 226-232
3. Ivanhoe C.B., Francisco G.E., McGuire J.R., Subramanian T., and Grissom S.P. Intrathecal baclofen management of poststroke spastic hypertonia: implications for function and quality of life. Arch Phys Med Rehabil 87 (2006) 1509-1515
4. Meythaler J.M., Guin-Renfroe S., Brunner R.C., and Hadley M.N. Intrathecal baclofen for spastic hypertonia from stroke. Stroke 32 (2001) 2099-2109
5. Ordia J.I., Fischer E., Adamski E., et al. Continuous intrathecal baclofen infusion by a programmable pump in 131 consecutive patients with severe spasticity of spinal origin. Neuromodulation 5 (2002) 16-24
6. Rizzo M.A., Hadjimichael O.C., Preiningerova J., and Vollmer T.L. Prevalence and treatment of spasticity reported by multiple sclerosis patients. Mult Scler 10 (2004) 589-595
7. Medtronic Inc. Medtronic Device Registration on File. "What is Medtronic ITB Therapy?". http://www.medtronic.com/your-health/cerebral-palsy/device/what-is-it/index.htm Accessed: October 8, 2009
8. Sigg J., Sonntag J.C., and Li J. Solubility and stability of intrathecal baclofen solutions at high concentrations: implications for chronic use in the synchromed infusion system. White Paper 2007 (2007), Medtronic Neurological, Minneapolis
9. Food and Drug Administration Modernization act of 1997. Public Law 105-115. 105th Congress. Food and Drug Administration. http://www.fda.gov/cder/guidance/105-115.htm Accessed January 10, 2009
10. Subramaniam P. Limited FDA survey of drug products (2003). http://www.fda.gov/cder/pharmcomp/survey.htm Accessed January 10, 2009
11. Azarnoff D.L., Lee J.C., Lee C., Chandler J., and Karlin D. Quality of extemporaneously compounded nitroglycerin ointment. Dis Colon Rectum 50 (2007) 509-516
12. Civen R., Vugia D.J., Alexander R., et al. Outbreak of Serratia marcescens infections following injection of betamethasone compounded at a community pharmacy. Clin Infect Dis 43 (2006) 831-837
13. Held M.R., Begier E.M., Beardsley D.S., et al. Life-threatening sepsis caused by Burkholderia Cepacia from contaminated intravenous flush solutions prepared by a compounding pharmacy in another state. Pediatrics 118 (2006) e212-e215
14. Sunenshine R.H., Tan E.T., Terashita D.M., et al. A multistate outbreak of Serratia marcescens bloodstream infection associated with contaminated intravenous magnesium sulfate from a compounding pharmacy. Clin Infect Dis 45 (2007) 527-533
15. Galson S. Federal and state role in pharmacy compounding. FDA congressional testimony Oct 23 (2003). www.fda.gov/ola/2003/pharmacycompound1023.html Accessed January 10, 2009
16. Pegues D.A. Improving and enforcing compounding pharmacy practices to protect patients. Clin Infect Dis 43 (2006) 838-840
17. Pharmaceutical considerations-sterile preparations. The United States Pharmacopeia. The United States Pharamcopeial Convention. 27th rev (2004) 2350-2370
18. Kastango E. Blueprint for implementing USP chapter 797 for compounding sterile preparations. Am J Health Syst Pharm 62 (2004) 1271-1288
19. Kastango E., and Bradshaw B. USP chapter 797: Establishing a practice standard for compounding sterile preparations in pharmacy. Am J Health Syst Pharm 61 (2004) 1928-1938
20. Candy T.A., Schneider P.J., and Pedersen C.A. Impact of United States pharmacopeia chapter 797: results of a national survey. Am J Health Syst Pharm 63 (2006) 1336-1343
21. Shirley K.W., Kothare S., Piatt J.H., and Adirim T.A. Intrathecal baclofen overdose and withdrawal. Pediatr Emerg Care 22 (2006) 258-261
22. Yeh R.N., Nypaver M.M., Deegan T.J., and Ayyangar R. Baclofen toxicity in an 8-year-old with an intrathecal baclofen pump. J Emerg Med 26 (2004) 163-167
23. Zuckerbraun N.S., Ferson S.S., Albright A.L., and Vogeley E. Intrathecal baclofen withdrawal: emergent recognition and management. Pediatr Emerg Care 20 (2004) 759-764
24. Coffey R.J., Edgar T.S., Francisco G.E., et al. Abrupt withdrawal from intrathecal baclofen: recognition and management of a potentially life-threatening syndrome. Arch Phys Med Rehabil 83 (2002) 735-741
25. Kinkade K. Pharmacy compounding: report on quality assurance initiatives in the state of Missouri and issues impacting consumer protection. Written testimony before the Health, Education, Labor and Pensions Committee US Senate. Hearing on federal and state role in pharmacy compounding and reconstitutions, exploring the right mix to protect patients. Oct 2003. http://www.fda.gov/ohrms/dockets/dockets/05p0116/05p-0116-cp00001-toc.htm Accessed January 10, 2009
26. Morris A.M., Schneider P.J., Pedersen C.A., and Mirtallo J.M. National survey of quality assurance activities for pharmacy-compounded sterile preparations. Am J Health Syst Pharm 60 (2003) 2567-2576
27. Fitch D.P., and Hall K.W. Survey of sterile product compounding practices in Canadian hospital pharmacies. Can J Hosp Pharm 46 (1993) 249-260
28. Papich M.G. Drug compounding for veterinary patients. AAPS J 7 (2005) E281-E287
29. Bernards C.M. Cerebrospinal fluid and spinal cord distribution of baclofen and bupivacaine during slow intrathecal infusion in pigs. Anesthesiology 105 (2006) 169-178
30. Nicol M.E., and Holdcroft A. Density of intrathecal agents. Br J Anaesth 68 (1992) 60-63
31. Young D. Outsourced compounding can be problematic. American Society of Health-System Pharmacists News. Dec 2003. http://www.ashp.org/import/News/HealthSystemPharmacyNews/newsarticle.aspx?id=1125 Accessed: October 1, 2009